Repligen Corp RGEN

Repligen Corp is an American bioprocessing company engaged in the development, production, and commercialisation of high-value, innovative products used in the process of manufacturing biologic drugs. The firm supplies a range of customers worldwide, including life sciences companies, global biopharmaceutical firms, and contract manufacturers. The firm was founded in 1981 and is based in Boston, Massachusetts. In addition to operating manufacturing sites in Massachusetts, Repligen Corp also owns sites in California, Sweden, and Germany.

The company has contributed to various important medical advances including products for cell culture intensification, tangential flow depth filtration, pre-packed columns, single-use cassettes, and integrated tangential flow filtration (TFF) systems. Repligen Corp is a leading manufacturer of Protein A affinity ligands, which are a critical component of Protein A resins used in the manufacture of monoclonal antibody therapeutics.

The firm’s products are marketed to customers across the globe through a direct commercial organisation operating in the United States, Europe, and Asia. Repligen Corp also works with strategic partners and distributors in select markets. The firm trades on the NASDAQ, where it is publicly listed under the stock ticker RGEN.

Use your eToro watchlist to monitor the RGEN price chart and receive real-time news updates and information on Repligen Corp.